Head-To-Head Review: Fluoropharma Medical (FPMI) vs. Vermillion (VRML)
Vermillion (NASDAQ:VRML) and Fluoropharma Medical (OTCMKTS:FPMI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.
This table compares Vermillion and Fluoropharma Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Vermillion and Fluoropharma Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vermillion presently has a consensus target price of $2.25, indicating a potential upside of 350.00%. Given Vermillion’s higher probable upside, research analysts plainly believe Vermillion is more favorable than Fluoropharma Medical.
Earnings and Valuation
This table compares Vermillion and Fluoropharma Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vermillion||$3.12 million||12.08||-$10.49 million||N/A||N/A|
|Fluoropharma Medical||N/A||N/A||-$2.04 million||N/A||N/A|
Fluoropharma Medical has lower revenue, but higher earnings than Vermillion.
Risk and Volatility
Vermillion has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Fluoropharma Medical has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.
Institutional and Insider Ownership
22.2% of Vermillion shares are owned by institutional investors. Comparatively, 0.5% of Fluoropharma Medical shares are owned by institutional investors. 4.3% of Vermillion shares are owned by company insiders. Comparatively, 36.9% of Fluoropharma Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Fluoropharma Medical beats Vermillion on 6 of the 9 factors compared between the two stocks.
Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
About Fluoropharma Medical
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.